Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced HR+/HER2- Breast Cancer Clear all

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 112 more

Conditions: PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2-low Breast Cancer
Interventions: CGT6297; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 9 more

Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer
Interventions: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX, Bevacizumab; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 13 more

Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Duarte, California • La Jolla, California • Denver, Colorado + 16 more

Conditions: Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions: TER-2013, Fulvestrant injection; Drug
Lead sponsor: Terremoto Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Duarte, California • Irvine, California • Orlando, Florida + 14 more

Conditions: Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation, HER2- Negative Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor, Cervical Cancer
Interventions: RGT-490; Drug
Lead sponsor: Regor Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania • Houston, Texas + 2 more

Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions: PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions: Samuraciclib, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more

Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
Interventions: OP-1250; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more

Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative
Interventions: CX-2009, CX-072; Drug
Lead sponsor: CytomX Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Breast Cancer, Solid Tumors
Interventions: PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more

Conditions: Breast Cancer
Interventions: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physician's choice; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 6 more

Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 32
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more

Conditions: Breast Cancer
Interventions: Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Fulvestrant, Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 34
States / cities: Chandler, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 31 more

Conditions: Advanced or Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Capecitabine, Paclitaxel, Nab-Paclitaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 866 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Scottsdale, Arizona • Springdale, Arkansas • Duarte, California + 23 more

Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions: STAR0602, Sacituzumab Govitecan (SG); Drug
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Columbus, Ohio + 2 more

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 40
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Afuresertib, Afuresertib/placebo; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Breast Cancer
Interventions: Ribociclib, Anastrozole, Letrozole, Goserelin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more

Search by objective public record fields.

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

A Study of PF-06873600 in People With Cancer

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer